This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.

Compact view
Research pass: stub-manual Compound SKIP-FOR-NOW MEDIUM

Setipiprant

Extended Research
High-risk compound

Surface here is educational only; do not use without medical supervision. Our editorial verdict is SKIP-FOR-NOW — current cost / risk / redundancy puts it below the line.

Extended Research

Our depth — beyond the mirror

Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.

Editor's verdict SKIP-FOR-NOW MEDIUM

Beautiful mechanistic story from Garza's Penn lab — but Kythera/Allergan Phase 2 in MPB did not meet endpoints clearly enough to advance, and the program has been quiet since. Research-chem supply unverified. No advantage over minoxidil + topical fin + ketoconazole at the current evidence level. Flips to WATCH-LIST only if a fresh trial (any sponsor) reads positive. For a 20yo with no MPB, nothing to evaluate.

Research pass: stub-manual
Verdict change log
  • 2026-06-05 — Initial verdict SKIP-FOR-NOW. Failed clinical program, no current case. (stub)

How was your experience with this compound?

Anonymous · one vote per session · results below at 5+ votes.

Loading…

See something off?

Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.

Discussion — click to load
Loading…